Ultrasonography-guided foam sclerotherapy in patients with small saphenous vein insufficiency

Memetoğlu, Mehmet Erdem; Yılmaz, Mehmet; Kehlіbar, Tamer; Günay, Rafet; Ketencі, Bülend; Demirtaş, Mahmut Murat; Özhan, Abdulkerim; Karakaya, Canan; Guler, Erhan

doi:10.1016/j.jvsv.2020.01.011

Cited by 10 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of truncal vein treatments involve foam polidocanol with a concentration ranging from 1% to 3%. The hyperpigmentation rates reported by all RCTs and non‐RCTs during this analysis (liquid and foam) were 7%–45.8% for polidocanol 1%, 21–26 16%–17% for polidocanol 2% 27,28 and 7.4%–32.5% for polidocanol 3% 21,22,24,25,28–30 …”

Section: Resultsmentioning

confidence: 72%

“…The hyperpigmentation rates reported by all RCTs and non-RCTs during this analysis (liquid and foam) were 7%-45.8% for polidocanol 1%, [21][22][23][24][25][26] 16%-17% for polidocanol 2% 27,28 and 7.4%-32.5% for polidocanol 3%. 21,22,24,25,[28][29][30] One randomized study compared polidocanol 3% liquid and polidocanol 3% foam. The authors found slightly less hyperpigmentation in the foam group than in the liquid group (7.4% vs. 9.6%) with almost the same injected volumes (liquid or emulsified foam).…”

Section: Telangiectasia and Reticular Varicose Veinsmentioning

confidence: 99%

See 1 more Smart Citation

Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review

Bossart

Daneluzzi

Cazzaniga

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Skin hyperpigmentation after sclerotherapy with polidocanol‐containing sclerosants is a common local side effect. Sclerotherapists should be familiar with factors that trigger hyperpigmentation after sclerotherapy with polidocanol‐containing sclerosants. A systematic literature review of works reporting hyperpigmentation after sclerotherapy for telangiectasias, reticular veins, side branches and truncal varices with polidocanol‐containing sclerosants was performed. Reported incidence rates, follow‐up periods and potentially triggering factors were assessed and analysed. The search yielded 1687 results; of these, 27 reports met the inclusion criteria. The incidence of hyperpigmentation seemed to increase with higher concentrations of polidocanol and was more evident after sclerotherapy for epifascial veins than for intrafascial truncal veins when the polidocanol concentration was more than 0.25%. Regarding sclerotherapy for telangiectasias and reticular veins, the incidence of hyperpigmentation ranged between 2% and 25% for polidocanol 0.25% (liquid and foam), between 12.5% and 67.9% for polidocanol 0.5% (liquid and foam) and between 13% and 73% for polidocanol 1% (liquid and foam). Regarding truncal veins, the incidence ranged from 7% to 45.8% for polidocanol 1% (liquid and foam), from 16% to 17% for polidocanol 2% (foam) and from 7.4% to 32.5% for polidocanol 3% (liquid and foam). Regarding the treatment of side branches, the incidence of hyperpigmentation ranged from 5.6% to 53% for both foam and liquid sclerotherapy. Regarding the duration of hyperpigmentation, there are few data describing reticular veins and telangiectasias. Hyperpigmentation persisting for more than 6 months has been reported to have an incidence of up to 7.5%. Hyperpigmentation persisting for more than 1 year after foam polidocanol 1%–3% treatment for truncal veins has an incidence ranging from 8.1% to 17.5%. Other factors such as higher volumes and compression therapy after treatment seem to have a minor influence. Data regarding hyperpigmentation after polidocanol‐related sclerotherapy are poor and should be improved by higher‐quality research.

show abstract

Section: Resultsmentioning

confidence: 72%

Section: Telangiectasia and Reticular Varicose Veinsmentioning

confidence: 99%

Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review

Bossart

Daneluzzi

Cazzaniga

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Sclerosing Foam (SF) is a therapeutic method that uses liquid hardening drugs to cause a sterile inflammatory reaction of the venous wall, resulting in venous formation of fibrous cord, which achieves the overall purpose of treating venous hypertension. [ 8 ] SF is accepted as a safe and effective treatment for venous insufficiency and especially for various venous diseases caused by venous hypertension. [ 9 – 13 ] Emerging evidence of several randomized controlled trials (RCTs) published in recent years suggests a benefit of SF in patients with VLUs.…”

Section: Introductionmentioning

confidence: 99%

The safety and efficacy of Sclerosing foam on treating venous leg ulcers

Fan

Yang

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Venous leg ulcers (VLUs) are common throughout the world, which seriously affects the patient's work and life. Relevant researches suggested that sclerosing foam (SF) has potential benefits for VLUs. However, there is no consistent conclusion. The purpose of our study is to assess whether SF is effective and safe for VLUs. Methods: Relevant clinical randomized controlled trials will be obtained from a search of 8 databases (with no language restrictions) from their inception to May 2020: PubMed, the Cochrane Library, EMBASE, Web of Science, China National Knowledge Infrastructure Database, Wanfang Database, China Science and Technology Journal Database, and Chinese Biological Medicine. Data will be analyzed using RevMan 5.3 after literature screening and data extraction according to predefined inclusion and exclusion criteria. Cochrane Collaboration Risk of bias Tool will be applied in evaluating the quality of enrolled articles. The primary outcome is Closure of venous leg ulcers, ulcer healing rate, adverse events related to SF. The secondary outcomes include ulcer healing time, ulcer recurrence rate, pain. Risk ratio will be used for categorical data; mean differences will be used for measurement data. Where possible and appropriate, meta-analysis will be performed for each outcome. Results: To clarify whether Sclerosing foam can be safe and efficient on treating venous leg ulcers. Conclusion: Our review will provide useful information to judge whether Sclerosing Foam is an effective and safe intervention for patients with venous leg ulcers.

show abstract

Lauromacrogol foam injection under ultrasonic guidance for pediatric lip venous malformations

Jiang

Zhu

et al. 2023

Pediatr Surg Int

View full text Add to dashboard Cite

Ultrasonography-guided foam sclerotherapy in patients with small saphenous vein insufficiency

Cited by 10 publications

References 15 publications

Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review

Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review

The safety and efficacy of Sclerosing foam on treating venous leg ulcers

Lauromacrogol foam injection under ultrasonic guidance for pediatric lip venous malformations

Contact Info

Product

Resources

About